Last update Aug. 6, 2017

Acarbose

Compatible

Safe substance and/or breastfeeding is the best option.

Alpha-glucosidase inhibitor which acts within the gastrointestinal tract without being absorbed, reducing intestinal absorption of glucose. Very low risk of hypoglycemia in monotherapy.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data (moderately elevated molecular weight and very low intestinal absorption) make it unlikely that it would pass to breast milk in significant amounts (Serrano 2014, Everett 1997).

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Acarbose is also known as


Acarbose in other languages or writings:

Group

Acarbose belongs to this group or family:

Tradenames

Main tradenames from several countries containing Acarbose in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0.7 - 2 %
Molecular weight 646 daltons
VD 0.3 l/Kg
Tmax 1 hours
T½ 2 - 3 hours

References

  1. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  2. Davis C. Acarbose. Drug Summary. 2015 Full text (in our servers)
  3. AEMPS. Acarbosa. Ficha técnica. 2009 Full text (in our servers)
  4. Nice FJ, De Eugenio D, Dimino TA, Freeny IC, Rovnack MB, Gromelski JS. Medications and Breast-Feeding: A Guide for Pharmacists, Pharmacy Technicians, and Other Healthcare Professionals. Part I. J Pharm Technol 2004;20:17-27. doi: 10.1177/875512250402000106.
  5. Everett JA. Use of oral antidiabetic agents during breastfeeding. J Hum Lact. 1997 Abstract
  6. Ahr HJ, Krause HP, Siefert HM, Steinke W, Weber H. Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C]acarbose to rats and dogs. Arzneimittelforschung. 1989 Abstract
  7. Ahr HJ, Boberg M, Krause HP, Maul W, Müller FO, Ploschke HJ, Weber H, Wünsche C. Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. Arzneimittelforschung. 1989 Abstract

Total visits

10,705

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM